Next Phase Newsletter

A private investment firm funded entirely by its partners based in the United States is looking to make equity investment into early and mid-stage life science companies ranging from $500,000 to 2 million initially. The firm looks to get involved in Seed and Series A Rounds. The firm could make as many as 6 investments over the next 12 months and looks to invest in companies located throughout the United States, Europe and Israel.

The firm is currently interested in sectors of Therapeutics, and Diagnostics. The firm is open to review all types of molecules and platforms and is currently most interested in for companies working towards indications of Autism, CNS disorders, and Parkinson’s disease. The firm generally looks to get involved with companies that are at the pre-clinical stage of development.

The firm is looking for companies with driven, and talented management teams with strong IP for their products. The firm is looking to invest in privately held companies and looks to take an active role following investment generally as a member of the Board. The firm is very comfortable working with scientific founding teams.

A private investment group based in Canada is looking to make growth stage investments in medical device companies. The firm does not manage a committed fund of capital. The firm’s partners generally make up 20-25% of the capital and raises additional capital on a deal-by-deal basis from a small group of high net worth investors. The firm invests in companies that are based in North America. The firm is actively looking for new investment opportunities.

In the Life Sciences the firm is currently seeking to invest in medical devices with market approval. The firm is opportunistic in terms of the class and indications. Historically, the firm invested in an image guided medical laser technology although they are open to all recently approved devices.

ECP seeks to be an active investor and will require a board seat/observer rights. The firm only invests in commercial stage companies but the firm does not have revenue requirements.

The corporate venture capital arm of a large health care system in the United States is looking to invest in on early-stage companies across the healthcare sector. The firm typically allocates $500K to $1.5M initially and up to $3M over the life of an investment. The firm looks for companies that are based in the United States and is actively seeking new investment opportunities.

In the Life Sciences the firm is currently seeking to invest in medical devices and diagnostics devices. The firm looks for all classes of devices and is opportunistic in terms of indications. The firm will consider devices as early as in development stage and all the way to commercialization stage. Current investments include companies operating in wound care, neurovascular and surgical tools though they are open to all types of medical devices. The firm is most interest in devices that have a strong potential to lower healthcare cost, thus benefiting the firm’s parents company. The firm looks to invest in privately held companies with a strong and experienced management team.

A private investment firm located in the Northeastern United Sates is looking to make investments in the life sciences space, and does so on a case by case basis without a traditional fund structure. Since the members are investing their own capital, the investment size and capital structure are highly flexible and will depend on the financial needs of the company. However the minimum amount the fund is willing to invest is $2 million, and can go upwards of $40 million. The firm invests in private or public companies and prefers to be the lead investor, but is open to syndicate as well. The firm is willing to invest in opportunities from all across the Globe. The firm is looking to conduct as many investments as possible over the course of the next 12 months, and is open to qualified deal flow.

The firm is very opportunistic and will consider a broad range of life science opportunities. The firm will consider Biotech, Medical Technology, R&D services, however the firm prefers not to invest in Healthcare IT, Dermatology, or Wound Care. The firm focuses on companies with clinical assets with some efficacy data, through those who have products on the market are also considered. The firm has a strong interest in technologies that significantly improve the standard of care.

The firm evaluates the company’s management team on a case by case basis. The firm is open to working with both experienced teams, as well as new entrepreneurs, and only requires that the team be competent. The firm does not require a board seat.

A family office with offices in the Northeast and Midwestern United Sates invests its principal capital into high growth companies in both the private and public sectors. The firm’s investment size is highly variable and dependent on the financial needs of the company. The firm often leads investment rounds and also has the ability to leverage its additional network of High-net worth families and like-mined co investors to syndicate for larger deals as well as follow on investments.  The firm looks to invest in companies throughout the United States and has no set number of investments in plans to make, however they are actively reviewing new opportunities.

Within healthcare, the firm is most interested in companies developing Devices and Diagnostics. The firm is looking for companies devices that solve a significant medical problem with strong IP supporting it. The firm is willing to invest in companies from the prototype stage to those that already have their product on the market and is generally agnostic in terms of indication. Historically the firm has invested in companies working with cardiac devices and also has held special interest in the pediatrics space. The firm is generally not as interested in consumer facing devices. The firm is also willing to consider investments in the Therapeutics space though this area is less of a focus.

The firm is looking for companies that have experienced management teams and a strong board behind them. The firm is willing to invest in both privately and public held companies with special interested in making PIPE investments. The firm looks to take a board seat into companies on a case by case basis.

The venture capital arm of a global pharmaceutical with has been established to invest in early stage ideas with breakthrough technologies addressing major unmet medical needs. The firm seeks to make equity investments in Seed and Series A/B rounds. The firm has a global mandate and is currently seeking new investment opportunities.

The firm is currently seeking to invest in early to mid-stage repurposed drugs, repositioned drugs, combination therapies, and new delivery technologies and devices for old drugs. In terms of indications, the firm is focused on oncology, neurology, infectious diseases, and metabolic diseases, but will consider other indications on a case-by-case basis. The firm will prioritize 505(b)(2) opportunities.

The firm seeks companies with a strong and experienced management team. The firm may take a board seat/board observer rights.

A private investment company established by a single high net worth individual is looking to make direct investments in the therapeutics space.  Based in New York City the firm manages an evergreen structure allowing it to have a very large range for investment size, capital structure, and holding period. The firm has no set number of allocations that it plans to make over the next 6-9 months and will evaluate all relevant opportunities on a case by case basis.

The firm is currently looking for US based companies in the therapeutics space and is open to considering both Biologics and Small Molecules. Companies with assets in phase II or later are of high interest, and companies in phase I that have some human efficacy data are also open to consideration. The firm is not interested in therapeutics areas with subjective endpoints such as pain and mental disorders.

The firm is looking for both private and micro-cap publicly held companies and evaluates management on a case by case basis. Taking a board seat is not a requirement for the firm and their involvement in the management of the firm varies based on the needs of the company. The firm is interested in both leading as well as co-investing in investment rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com